Posts by Stephanie Kolp
Can AI Eliminate “Dead Time” in Drug Development?
FDA’s Emerging Vision for Real-Time Clinical Trials
Over the last 10-15 years, the amount of time spent between clinical trials, including administrative closeout and key decision points, has significantly increased. A new initiative by FDA aims to reduce “dead time” between clinical trial phases.
Read MoreSolving Operational Complexity in ADC Oncology Trials: From Design to Execution
Many sponsors encounter a consistent challenge: ADC clinical trials introduce a level of operational complexity that goes well beyond traditional oncology trials.
Read MoreHow Bayesian Dose-Finding Designs Can Accelerate Early-Phase Oncology Clinical Research
Historically used more frequently in exploratory analyses, Bayesian approaches are now increasingly recognized as viable frameworks for primary analysis in drug and biologic development—when appropriately designed and justified.
Read MoreEverest Clinical Research Named Finalist of Fierce Outsourcing Awards for Excellence in Client Partnership
Everest Clinical Research has been named a 2026 finalist in the Excellence in Client Partnership category for the Fierce Outsourcing Awards.
Read MoreWho Should Own Your Clinical Study URL? A Practical Guide for Sponsors
It sounds like a small administrative detail—but in practice, URL ownership shapes how your trial operates from day one through closeout. It can influence everything from study startup timelines to change control processes, migration costs, and long-term data governance.
Read MoreEverest Clinical Research and the Friedreich’s Ataxia Research Alliance (FARA) Announce Biostatistics Partnership to Advance Research in Friedreich’s Ataxia
TORONTO and PHILADELPHIA — February 27, 2026 —Everest Clinical Research and the Friedreich’s Ataxia Research Alliance (FARA) today announced a partnership focused on making patient-centered Friedreich’s ataxia (FA) data more accessible and actionable to help accelerate the development of treatments for FA. As part of the collaboration, Everest Clinical Research will serve as a biostatistics…
Read MoreEverest Clinical Research to Expand Asia Pacific Operations with New Biometrics Team in the Philippines
Expansion will strengthen global biometrics delivery and support continued growth across the globe TORONTO — February 3, 2026 –Everest Clinical Research, a leading full-service contract research organization (CRO) with deep biometrics foundations, announces the expansion of its Asia Pacific operations with the establishment of a new biometrics team in the Philippines. The company expects to…
Read MoreEverest Clinical Research Welcomes Amy Nguyen as Chief Commercial Officer to Drive Continued Global Growth
TORONTO, December 17, 2025 — Everest Clinical Research, a global, full-service CRO, announces the appointment of Amy Nguyen as the company’s first Chief Commercial Officer (CCO). In this new role, Nguyen will build upon Everest’s commercial operations while driving sales and pipeline planning to support the company’s growing client base from the earliest stages of…
Read MoreEverest Strengthens Global Biometrics Capabilities with Expansion in Poland
TORONTO – November 24, 2025 – Everest Clinical Research— a data-driven and quality-focused global CRO — is pleased to announce the establishment of a dedicated biometrics team, providing clinical data management, biostatistics, and statistical programming services in Warsaw, Poland. This strategic expansion builds on Everest’s already strong presence in Poland, where the company provides local…
Read More